Lexicon Pharmaceuticals, Inc. announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® (sotagliflozin) use in heart failure (HF) and major adverse cardiovascular events (MACE) related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events. The data were shared in an oral presentation by Rahul Aggarwal, M.D., Brigham and Women?s Hospital, Boston, Massachusetts, at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Pennsylvania. The goal of the analysis was to evaluate the time to clinical benefit for HF and MACE related outcomes in patients at high risk for cardiovascular events and treated with sotagliflozin.

For total cardiovascular deaths, hospitalizations for HF, or urgent visits for HF, the primary endpoint of the trial, the relative risk reduction observed in patients treated with sotagliflozin vs. placebo was 26% (HR=0.74; 95% CI, 0.63, 0.88; p· type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.